ArticleBritish journal of cancer2002
Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma.
Article in British journal of cancer, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Global gene expression landscape of gallbladder cancer and advances in targeted therapeutic strategies.World journal of clinical oncology · 2025Review
- Integrated analysis ofCell cycle (Georgetown, Tex.) · 2024Review
- Article
- Protein expression of Fragile Histidine Triad and cyclooxgenase-2 in serrated neoplasia of the colorectum.Oncology letters · 2017Article
- AID, p53 and MLH1 expression in early gastric neoplasms and the correlation with the background mucosa.Oncology letters · 2015Article
- Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2013Article
- Expression of AID, P53, and Mlh1 proteins in endoscopically resected differentiated-type early gastric cancer.World journal of gastrointestinal oncology · 2012Article
- Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis.International journal of colorectal disease · 2007Article
- MSI/LOH and extron expression of the FHIT gene in gastric carcinoma.Frontiers of medicine in China · 2007Article
- Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma.World journal of gastroenterology · 2006Article
- Common fragile genes and digestive tract cancers.Surgery today · 2006Review
- Relationship between abnormality of FHIT gene and EBV infection in gastric cancer.World journal of gastroenterology · 2005Article
- Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis.World journal of gastroenterology · 2005Article
- Fhit expression in human gastric adenomas and intramucosal carcinomas: correlation with Mlh1 expression and gastric phenotype.British journal of cancer · 2004Article
- Cancer and the FRA3B/FHIT fragile locus: it's a HIT.British journal of cancer · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Fragile Histidine Triad gene, encompassing the FRA3B fragile site at chromosome 3p14.2, is a candidate tumour suppressor gene involved in multiple tumour types including colorectal carcinomas. Recently, it has been reported that the Fragile Histidine Triad gene may be a target of damage in a fraction of mismatch deficient tumours. To explore this hypothesis, we analysed both Fragile histidine triad and mismatch repair protein (Msh2 and Mlh1) expression using immumohistochemical methods in 52 advanced colorectal carcinomas (19 well-, 17 moderately-, and 16 poorly-differentiated). In addition, we examined whether the Fragile histidine triad and mismatch repair protein expression correlated with p53 expression and clinicopathological findings. Significant loss or reduction of Fragile histidine triad expression was noted in 18 of the 52 (34.6%) advanced colorectal carcinomas: 2 (10.5%) well-differentiated, 3 (17.6%) moderately-differentiated, 13 (81.3%) poorly-differentiated carcinomas, the frequency being significantly higher in the latter than that in the former two (P<0.0001). Loss of mismatch repair protein (mainly, Mlh1) expression was detected in 21 of the 52 (40.4%) colorectal carcinomas. Moreover, reduced Fragile histidine triad expression was significantly associated with absence of mismatch repair protein expression in the advanced colorectal carcinomas (P<0.0001). However, the Fragile histidine triad and mismatch repair protein expression was not significantly associated with p53 expression. These results suggested that reduced Fragile histidine triad expression might be correlated with mismatch repair expression, but not with p53 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.